scPharmaceuticals Inc
NASDAQ:SCPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Cargotec Corp
OMXH:CGCBV
|
FI |
|
Fingerprint Cards AB
STO:FING B
|
SE |
|
R
|
RVRC Holding AB
STO:RVRC
|
SE |
|
Kidsland International Holdings Ltd
HKEX:2122
|
CN |
|
Whirlpool Corp
NYSE:WHR
|
US |
scPharmaceuticals Inc
Operating Expenses
scPharmaceuticals Inc
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
scPharmaceuticals Inc
NASDAQ:SCPH
|
Operating Expenses
-$113.8m
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Operating Expenses
-$38.6B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Expenses
-$17.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-5%
|
|
|
Pfizer Inc
NYSE:PFE
|
Operating Expenses
-$27.5B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Expenses
-$26.2B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-5%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Expenses
-$24.4B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-8%
|
|
scPharmaceuticals Inc
Glance View
scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. The company is headquartered in Burlington, Massachusetts and currently employs 26 full-time employees. The company went IPO on 2017-11-17. The firm is focused on exploring, developing and commercializing products that expand and advance the outpatient care of acute conditions, including worsening heart failure and bacterial infections requiring outpatient parenteral antimicrobial therapy. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infusor and is under development for treatment of congestion in patients with heart failure who display reduced responsiveness to oral diuretics and do not require hospitalization. Its area of focus is congestion in heart failure and outpatient parenteral antimicrobial therapy (OPAT). Its pipeline programs include FUROSCIX, scCeftriaxone and scCarbapenem. Its FUROSCIX On-Body Infusor is a drug-device combination product consisting of FUROSCIX. The firm's wholly owned subsidiary is scPharmaceuticals Securities Corporation.
See Also
What is scPharmaceuticals Inc's Operating Expenses?
Operating Expenses
-113.8m
USD
Based on the financial report for Jun 30, 2025, scPharmaceuticals Inc's Operating Expenses amounts to -113.8m USD.
What is scPharmaceuticals Inc's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-30%
Over the last year, the Operating Expenses growth was -47%. The average annual Operating Expenses growth rates for scPharmaceuticals Inc have been -57% over the past three years , -30% over the past five years .
